Psychosocial Intervention for Suicidal Ideation in Individuals With FEP: A Feasibility Trial
CMAP-FEP
Culturally Adapted Psychosocial Intervention for Suicidal Ideation in Individuals With First Episode Psychosis: A Feasibility Randomised Controlled Trial
1 other identifier
interventional
80
1 country
1
Brief Summary
To check the feasibility and acceptability of Culturally adapted Cognitive Behavioral Therapy for Psychosis (CaCBTp) and Culturally Adapted Manual Assisted Brief Psychological Intervention for Self-harm (CMAP), which we have provisionally called (CMAP Plus) for individuals experiencing Suicidal Ideation (SI) in First Episode Psychosis (FEP).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2023
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 4, 2023
CompletedFirst Posted
Study publicly available on registry
February 14, 2023
CompletedStudy Start
First participant enrolled
November 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2025
CompletedJanuary 3, 2025
January 1, 2025
1.7 years
February 4, 2023
January 1, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Feasibility Indicator
feasibility will be determined by collecting data on recruitment and retention rates. The success criterion of feasibility will be to recruit \> 50% of eligible participants
From baseline to 12th week (end of intervention)
Acceptability Indicator
Intervention acceptability will be assessed using data on attendance. Criterion for acceptability is a mean attendance rate of \>70%.
From baseline to 12th week (end of intervention)
Secondary Outcomes (7)
Positive and Negative Syndrome Scale
From baseline to 12th week (end of intervention)
Beck Scale for Suicidal Ideation
From baseline to 12th week (end of intervention)
Medication Adherence Rating Scale
From baseline to 12th week (end of intervention)
Calgary Depression Scale
From baseline to 12th week (end of intervention)
The Work and Social Adjustment Scale
From baseline to 12th week (end of intervention)
- +2 more secondary outcomes
Study Arms (2)
CMAP Plus FEP
EXPERIMENTALParticipants with First episode of psychosis, Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT)
treatment as usual
NO INTERVENTIONParticipants in this group will continue their routine treatment as prescribed by their responsible clinician. In Pakistan TAU mostly comprise of antipsychotics with few patients having access to psychological therapies. Research staff will record the nature and intensity of the TAU for each participant
Interventions
Culturally Adapted Manual Assisted Problem Solving (CMAP) integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), integrated with Culturally adapted Cognitive Behavior Therapy (CaCBT) including 12 sessions delivered over three months. This intervention includes evaluation of the self-harm attempt, psycho-education, crisis skills, problem-solving and simple and thought management
Eligibility Criteria
You may qualify if:
- Individuals diagnosed with, Schizophrenia or Schizoaffective disorder according to DSM-V, confirmed by treating consultant.
- Age 18 and above years able to understand written and spoken Urdu.
- A score of 1 (Mild- Frequent thoughts of being better off dead, or occasional thoughts of suicide.) on the Calgary depression Scale item 8 (Suicide) "Have you felt that life wasn't worth living? Did you ever feel like ending it all? What did you think you might do? Did you actually try?"
- Individuals with a score of 3 or more on any of the positive symptoms on the Positive and Negative Syndrome Scale (PANSS) (e.g., delusions, hallucination).
You may not qualify if:
- Any evidence of organic brain disease, clinically significant comorbid illness or learning disability. Participants deemed actively suicidal by their designated health professional.
- Those scoring \>1 on Calgary depression Scale will be excluded and be referred to a psychiatric service.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Karwan e Hayat
Karachi, Sindh, 75600, Pakistan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Imran Chaudhry
Ziauddin Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 4, 2023
First Posted
February 14, 2023
Study Start
November 1, 2023
Primary Completion
June 30, 2025
Study Completion
October 30, 2025
Last Updated
January 3, 2025
Record last verified: 2025-01
Data Sharing
- IPD Sharing
- Will not share